Indian Biotech Startup Announces Breakthrough In Molecular Diagnostics To Detect Early Stage Cancer With Simple Blood Test

Tzar Labs, a specialised molecular diagnostic company, along with Mumbai-based Epigeneres Biotechnology, has made a breakthrough in early-detection and diagnosis of cancer.

This is possible with a novel blood test that can help determine whether cancer is absent, imminent, or present, and also detect different stages of the disease. This will pave the way for widespread early detection and treatment of cancer, thereby potentially saving millions of lives.

“This innovation will redefine cancer diagnostics through precise and accurate detection before any symptoms or tumours develop. The discovery enables the detection of cancer and the stage of the disease from a simple blood test with virtually 100 per cent accuracy,” the company said.

The company has done a clinical study of 1000 subjects, and published its peer-reviewed paper in Stem Cell Reviews and Reports (SCRR).

Commenting on this major milestone, Ashish Tripathi, Founder and CEO of Tzar Labs, said, “We are delighted to announce that our team of Indian Scientists have made this significant breakthrough that will change the way we address, understand, detect and treat all kinds of Cancers. We can detect cancer earlier than known technologies when the disease is infinitely more treatable. What we will provide is better information to Oncologists, for making treatment-related decisions, and thus saving lives.”

According to the company, Tzar Labs has pioneered a proprietary technology which can detect organ-level RNA mutations directly from the blood. They have been carrying out extensive research on marker genes and found the key molecular indicator of cancerous conditions. The company has filed patents in the US, Europe, Japan, China, and Singapore amongst others, for this innovation in diagnostic technology.

Tzar Labs has co-developed this technology with Indian molecular medicine start-up Epigeneres Biotech.

Mumbai-based nanotech scientist Vinay Kumar Tripathi and his family are majority shareholders in both companies. Tripathi’s youngest son is the best-selling author Amish Tripathi, best known for the series Shiva Trilogy. His two other sons Ashish and Anish, a former investment banker and consultant respectively are involved in the management of the two companies.